Non-invasive white cell counts at the tip of your finger
Reduced chemotherapy cycle time
White cell counts
Imagine a phone-sized blood cell counter that needs no blood. Innovative optics see through the skin, and count white cells as they flow past a miniature lens.
White cells count
The white cell count is the first line indicator for medical applications ranging from chemotherapy management to the detection of life threatening infection in a targeted world population of 4 billion people.
Team Leuko featured at the news in Spanish National Television, January 2016
We learned that many cancer patients can tolerate a higher frequency of chemotherapy infusions than they typically get, and that with a higher frequency comes the high potential for better treatment outcomes. So we began to develop a personalized daily home blood test that will indicate when patients are ready for the next infusion ahead of the typical scheduling. Our optics-based test is non-invasive, detecting key informative blood cells through the skin without pain.. A potentially transformative improvement in chemotherapy management.
The key blood cells for our cancer application are also the key blood cells detected in acute infection. A simple test for these cells is sought throughout the resource poor regions of the world; especially where HIV-associated bacterial co-infection is endemic. This niche alone would account for approximately 40 million tests per year. There are approximately 4 billion people living in rural regions of our planet who currently have little or no access to testing for infection, which we've set out to provide.
The project is completing its proof of principle phase and entering its first clinical tests. By December 2016, two working prototypes completed their first round of clinical testing and design revision.
Carlos Castro-González, PhD
Project management, image analysis and fundraising.
Carolina Cerrato, MD. Hospital La Paz, Madrid, Spain. Rafael Flores, MD. Hospital de Fuenlabrada, Madrid, Spain. Ephraim Hochberg, MD. Massachusetts General Hospital, Boston, USA.
Scientific Advisory Board
Isabela Alcázar, PhD, MBM. Polypeptide Therapeutic Solutions S.L., Madrid, Spain. |
Martha Gray, PhD. Massachusetts Institute of Technology, Cambridge, USA. |
Peter Hansen, PhD. Union Biometrica Technology Inc., Holliston, USA. |
Petra Krauledat, PhD. PNPResearch Corporation, Cambridge, USA. |
María J. Ledesma-Carbayo, PhD. Universidad Politécnica de Madrid, Madrid, Spain. |
Jerome Mertz, PhD. Boston University, Boston, USA. |
Arrate Muñoz-Barrutia, PhD. Universidad Carlos III, Madrid, Spain. |
Francisca Mulero, PhD. Centro Nacional de Investigaciones Oncológicas, Madrid, Spain. |
Timothy Padera, PhD. Harvard Medical School, Boston, USA. |
Tom Vettenburg, PhD. Universidad Carlos III, Madrid, Spain.